Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
January 8, 2017Global Phase 3 Program Top-Line Results Expected Mid-2018
More »
Marinus Provides Business Outlook for 2017
January 5, 2017Several Data Milestones Anticipated With Ganaxolone
More »
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
January 3, 2017Marinus Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).
More »